Annals of Oncology - New goals
Read the latest Editorial from Professor Soria reflecting on the past two years of Annals of Oncology and looking to the future of the journal.
Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up
H. Kadara; M. Choi; J. Zhang; E. R. Parra; J. Rodriguez-Canales ...
Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function
M. Choi; H. Kadara; J. Zhang; E.R. Parra; J. Rodriguez-Canales ...
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone
C. Massard; J. Mateo; Y. Loriot; C. Pezaro; L. Albiges ...
Practical guidance for mismatch repair-deficiency testing in endometrial cancer
E. Stelloo; A. M. L. Jansen; E. M. Osse; R. A. Nout; C. L. Creutzberg ...
Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab
J.-Y. Pierga; F.-C. Bidard; A. Autret; T. Petit; F. Andre ...
Impact of early palliative care on caregivers of patients with advanced cancer: cluster randomised trial
J. McDonald; N. Swami; B. Hannon; C. Lo; A. Pope ...
Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine
F. Husseini; J.-P. Delord; C. Fournel-Federico; J. Guitton; P. Erbs ...
Common breast cancer risk alleles and risk assessment: a study on 35 441 individuals from the Danish general population
C. Näslund-Koch; B. G. Nordestgaard; S. E. Bojesen
Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment
E. An; C.-Y. Ock; T.-Y. Kim; K.-H. Lee; S.-W. Han ...
Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003)
M. Yamasaki; T. Yasuda; M. Yano; M. Hirao; K. Kobayashi ...
A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas
M. Agulnik; R. L. B. Costa; M. Milhem; A. W. Rademaker; B. C. Prunder ...
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial
W. Shi; T. Jiang; P. Nuciforo; C. Hatzis; E. Holmes ...
Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations
E. Iwama; K. Sakai; K. Azuma; T. Harada; D. Harada ...
Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma
S. M. Dieter; C. Heining; A. Agaimy; D. Huebschmann; D. Bonekamp ...
Cyclin D mediates tolerance of genome-doubling in cancers with functional p53
A. Crockford; L. P. Zalmas; E. Grönroos; S. M. Dewhurst; N. McGranahan ...
Do Contemporary Randomized Controlled Trials Meet ESMO Thresholds for Meaningful Clinical Benefit?
J. C. Del Paggio; B. Azariah; R. Sullivan; W. M. Hopman; F. V. James ...
‘Genotype/immunotype’ correlations in resected NSCLC
P. K. Paik; M. D. Hellmann
Antiangiogenic therapies in gastric cancer: trusting the pathway
M. Alsina; C. Hierro; J. Tabernero
On the generalizability of prostate cancer studies: why race matters
O. Oren; M. Oren; D. Beach
Ovarian cancer mortality trends: which factors are involved?
E. Weiderpass; E. Botteri
Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives
R. Costa; B. A. Carneiro; D. A. Wainwright; C. A. Santa-Maria; P. Kumthekar ...
Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment
C. S. Voican; O. Mir; P. Loulergue; M. Dhooge; C. Brezault ...
Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis
C. Coyle; F. H. Cafferty; C. Vale; R. E. Langley
The obese endometrial cancer patient: how do we effectively improve morbidity and mortality in this patient population?
K. Papatla; M. Huang; B. Slomovitz
Fertility-sparing surgery in epithelial ovarian cancer: a systematic review of oncological issues
E. Bentivegna; S. Gouy; A. Maulard; P. Pautier; A. Leary ...
Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape
K. A. Olaussen; S. Postel-Vinay
Impact Factor increases to 9.269
Access our free collection of highly cited articles which contributed to Annals of Oncology’s new Impact Factor of 9.269
World Cancer Day 2017
Explore the Annals of Oncology World Cancer Day collection, focusing on taking action against, and preventing cancer.
The Best of 2016
Explore a collection of the best articles of 2016 from Annals of Oncology.
Why Publish with Annals of Oncology?
Give your research the global platform it deserves; submit to Annals of Oncology, one of the most widely read and cited journals in Oncology.
Bioinformatics: breaking the bottleneck for cancer research. A new series in Annals of Oncology with Associate Editor Nicholas McGranahan
Industry corner: perspectives and controversies. A new series in Annals of Oncology with Associate Editor Kapil Dhingra